PreveCeutical Medical (TSE:PREV) has released an update.
PreveCeutical Medical’s subsidiary, BioGene Therapeutics, has appointed Dr. Mariya Georgieva as President to lead advancements in siRNA therapy for diabetes and obesity. Dr. Georgieva brings valuable experience from AstraZeneca, enhancing BioGene’s research capabilities in metabolic health and gene-based treatments.
For further insights into TSE:PREV stock, check out TipRanks’ Stock Analysis page.
